• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Teva Pharmaceutical Industries Limited American Depositary Shares (NY:TEVA)

36.93 -0.41 (-1.10%)
Official Closing Price Updated: 6:30 PM EDT, Aug 24, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 3,338,942
Open 37.30
Bid (Size) 36.51 (100)
Ask (Size) 37.05 (200)
Prev. Close 37.34
Today's Range 36.75 - 37.32
52wk Range 17.82 - 37.83
Shares Outstanding 1,110,352,397
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
U.S. FDA Accepts Teva’s New Drug Application (NDA) and Grants Priority Review for Ecopipam, a First-in-Class Investigational Therapy for Pediatric Patients with Tourette Syndrome
August 19, 2026
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
News headline image
Moody’s Ratings Upgrades Teva to Investment Grade, Reflecting the Ongoing Execution of Pivot to Growth Strategy
August 11, 2026
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire

Performance

YTD
+19.3%
+19.3%
1 Month
+19.9%
+19.9%
3 Month
+6.7%
+6.7%
6 Month
+8.9%
+8.9%
1 Year
+103.8%
+103.8%

More News

Read More
News headline image
Teva (TEVA) Q2 2026 Earnings Call Transcript ↗
August 07, 2026
Via The Motley Fool
Topics Earnings
News headline image
Why Teva Pharmaceutical Stock Surged This Week ↗
August 02, 2026
Via The Motley Fool
Topics Stocks
News headline image
Teva Pharmaceutical Industries Q2 Earnings Call Highlights ↗
July 30, 2026
Via MarketBeat
Topics Earnings
News headline image
Teva Delivers Strong Q2 Results and Raises Outlook for All Three Key Innovative Brands, Reflecting Continued Execution of Its Pivot to Growth Strategy
July 29, 2026
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
News headline image
Teva's Turnaround Is Working. Here's the 1 Thing That Could Send It Soaring Another 50%. ↗
July 26, 2026
Via The Motley Fool
News headline image
Wall Street Thinks Teva Can Soar Over 60%. Here's Why Analysts Are Right. ↗
July 26, 2026
Via The Motley Fool
Topics Intellectual Property
News headline image
Teva Pharmaceutical Industries’ Anti-IL-15 Antibody Shows Promise in Vitiligo Study ↗
July 12, 2026
Via MarketBeat
News headline image
Novartis vs. Teva: Which Pharmaceutical Stock Is a Better Buy in 2026? ↗
July 09, 2026
Via The Motley Fool
News headline image
Teva and Polpharma Biologics Announce Global Licensing Agreement for a Biosimilar Candidate to Ocrevus® (ocrelizumab) for Multiple Sclerosis
July 09, 2026
From Polpharma Biologics International AG
Via Business Wire
News headline image
Teva and Polpharma Biologics Announce Global Licensing Agreement for a Biosimilar Candidate to Ocrevus® (ocrelizumab) for Multiple Sclerosis
July 09, 2026
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
News headline image
Teva to Advance Its Anti-IL-15 Antibody, Designed for Quarterly Dosing, Into Phase 2b Development in Vitiligo, Following Encouraging Phase 1b Results
July 07, 2026
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
News headline image
Eli Lilly and vs. Teva: Which Pharmaceutical Stock Is a Better Buy in 2026? ↗
July 06, 2026
Via The Motley Fool
News headline image
Teva Just Delivered More Good News on Its Biggest Growth Driver. Is the Stock Still a Bargain? ↗
June 19, 2026
Via The Motley Fool
News headline image
Teva Releases Q2 2026 Aide Memoire
June 18, 2026
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
News headline image
Teva Submits NDA for Ecopipam, a First-in-Class Investigational Therapy for Pediatric Tourette Syndrome
June 18, 2026
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
News headline image
Teva to Host Conference Call to Discuss Second Quarter 2026 Financial Results on July 29, 2026 at 8 a.m. ET
June 18, 2026
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
News headline image
Teva's Biosimilar Boom Is Just Getting Started. Is It Time to Buy This Rebounding Pharma Stock? ↗
June 12, 2026
Via The Motley Fool
Topics Intellectual Property
News headline image
Teva Closes Acquisition of Emalex Biosciences, Strengthening Late-Stage Neuroscience Pipeline and Advancing Pivot to Growth Strategy
June 10, 2026
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
News headline image
Teva’s Data on AUSTEDO® (deutetrabenazine) tablets and AUSTEDO XR® (deutetrabenazine) extended-release tablets Highlight Long-Term Advances in Tardive Dyskinesia Treatment and Care
June 08, 2026
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
News headline image
Alvotech announces FDA acceptance of Biologics License Application for AVT16, a proposed interchangeable biosimilar to Entyvio®
June 08, 2026
From Alvotech
Via GlobeNewswire
News headline image
Teva Presents New Data on AUSTEDO® (deutetrabenazine) tablets and AUSTEDO XR® (deutetrabenazine) extended-release tablets that Show Patient- and Caregiver-Reported Improvements in Huntington's Disease Chorea
June 05, 2026
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
News headline image
Teva Expands European biosimilars portfolio with launch of AHZANTIVE® (aflibercept) biosimilar to Eylea®
June 04, 2026
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
News headline image
Alvotech announces resubmission of U.S. Biologics License Applications for AVT05, a proposed biosimilar to Simponi® and Simponi Aria®, and AVT06, a proposed biosimilar to Eylea®
June 04, 2026
From Alvotech
Via GlobeNewswire

Frequently Asked Questions

Is Teva Pharmaceutical Industries Limited American Depositary Shares publicly traded?
Yes, Teva Pharmaceutical Industries Limited American Depositary Shares is publicly traded.
What exchange does Teva Pharmaceutical Industries Limited American Depositary Shares trade on?
Teva Pharmaceutical Industries Limited American Depositary Shares trades on the New York Stock Exchange
What is the ticker symbol for Teva Pharmaceutical Industries Limited American Depositary Shares?
The ticker symbol for Teva Pharmaceutical Industries Limited American Depositary Shares is TEVA on the New York Stock Exchange
What is the current price of Teva Pharmaceutical Industries Limited American Depositary Shares?
The current price of Teva Pharmaceutical Industries Limited American Depositary Shares is 36.93
When was Teva Pharmaceutical Industries Limited American Depositary Shares last traded?
The last trade of Teva Pharmaceutical Industries Limited American Depositary Shares was at 08/24/26 06:30 PM ET
What is the market capitalization of Teva Pharmaceutical Industries Limited American Depositary Shares?
The market capitalization of Teva Pharmaceutical Industries Limited American Depositary Shares is 41.01B
How many shares of Teva Pharmaceutical Industries Limited American Depositary Shares are outstanding?
Teva Pharmaceutical Industries Limited American Depositary Shares has 41B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap